JankovicV1, PascalFrancis, Checkpoint, bibRecord, 000156

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Identifieur interne : 000156 ( PascalFrancis/Checkpoint ); précédent : 000155; suivant : 000157

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Auteurs : Joseph Jankovic [États-Unis]

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 2000.

RBID : Pascal:01-0069947

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Antiparkinsonien, Sélégiline, IMAO B, Récepteur dopaminergique, Agoniste, Transmission cholinergique, Inhibiteur enzyme, Homme, Traitement, Chimiothérapie, Essai thérapeutique contrôlé, Activité biologique, Article synthèse, Catechol O-methyltransferase.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Biological activity, Catechol O-methyltransferase, Chemotherapy, Cholinergic transmission, Controlled therapeutic trial, Dopamine receptor, Enzyme inhibitor, Human, Levodopa, MAO B inhibitor, Parkinson disease, Review, Selegiline, Treatment.

Abstract

Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000154
to stream PascalFrancis, to step Curation: 000012

Links to Exploration step

Pascal:01-0069947

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0069947</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0069947 INIST</idno>
<idno type="RBID">Pascal:01-0069947</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000154</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000012</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000156</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Biological activity</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Cholinergic transmission</term>
<term>Controlled therapeutic trial</term>
<term>Dopamine receptor</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Levodopa</term>
<term>MAO B inhibitor</term>
<term>Parkinson disease</term>
<term>Review</term>
<term>Selegiline</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Sélégiline</term>
<term>IMAO B</term>
<term>Récepteur dopaminergique</term>
<term>Agoniste</term>
<term>Transmission cholinergique</term>
<term>Inhibiteur enzyme</term>
<term>Homme</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Essai thérapeutique contrôlé</term>
<term>Activité biologique</term>
<term>Article synthèse</term>
<term>Catechol O-methyltransferase</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>252-261</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000093580530030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>113 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0069947</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sélégiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Selegiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Selegilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>IMAO B</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>MAO B inhibitor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>IMOA B</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Transmission cholinergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cholinergic transmission</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Transmisión colinérgica</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Essai thérapeutique contrôlé</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Controlled therapeutic trial</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ensayo terapéutico controlado</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Review</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fN21><s1>043</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000156 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000156 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:01-0069947
   |texte=   Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
}}

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour de Joseph Jankovic

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri